Back to Search Start Over

Proteogenomic analysis of the total and surface-exposed proteomes of Plasmodium vivax salivary gland sporozoites

Authors :
Ribeiro, JMC
Swearingen, KE
Lindner, SE
Flannery, EL
Vaughan, AM
Morrison, RD
Patrapuvich, R
Koepfli, C
Muller, I
Jex, A
Moritz, RL
Kappe, SHI
Sattabongkot, J
Mikolajczak, SA
Ribeiro, JMC
Swearingen, KE
Lindner, SE
Flannery, EL
Vaughan, AM
Morrison, RD
Patrapuvich, R
Koepfli, C
Muller, I
Jex, A
Moritz, RL
Kappe, SHI
Sattabongkot, J
Mikolajczak, SA
Publication Year :
2017

Abstract

Plasmodium falciparum and Plasmodium vivax cause the majority of human malaria cases. Research efforts predominantly focus on P. falciparum because of the clinical severity of infection and associated mortality rates. However, P. vivax malaria affects more people in a wider global range. Furthermore, unlike P. falciparum, P. vivax can persist in the liver as dormant hypnozoites that can be activated weeks to years after primary infection, causing relapse of symptomatic blood stages. This feature makes P. vivax unique and difficult to eliminate with the standard tools of vector control and treatment of symptomatic blood stage infection with antimalarial drugs. Infection by Plasmodium is initiated by the mosquito-transmitted sporozoite stage, a highly motile invasive cell that targets hepatocytes in the liver. The most advanced malaria vaccine for P. falciparum (RTS,S, a subunit vaccine containing of a portion of the major sporozoite surface protein) conferred limited protection in Phase III trials, falling short of WHO-established vaccine efficacy goals. However, blocking the sporozoite stage of infection in P. vivax, before the establishment of the chronic liver infection, might be an effective malaria vaccine strategy to reduce the occurrence of relapsing blood stages. It is also thought that a multivalent vaccine comprising multiple sporozoite surface antigens will provide better protection, but a comprehensive analysis of proteins in P. vivax sporozoites is not available. To inform sporozoite-based vaccine development, we employed mass spectrometry-based proteomics to identify nearly 2,000 proteins present in P. vivax salivary gland sporozoites. Analysis of protein post-translational modifications revealed extensive phosphorylation of glideosome proteins as well as regulators of transcription and translation. Additionally, the sporozoite surface proteins CSP and TRAP, which were recently discovered to be glycosylated in P. falciparum salivary gland sporozoites, w

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1315699454
Document Type :
Electronic Resource